Gyre Therapeutics (GYRE) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 15.8% versus a loss of 3.2%. Over five years, LXRX leads with a -71.4% price change compared with -88.3% for GYRE. Lexicon Pharmaceuticals is the larger company by market cap ($783.1 million vs $746.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | LXRX |
|---|---|---|
| Share price | $7.04 | $1.76 |
| Market cap | $746.48M | $783.12M |
| 1-day change | -0.56% | +0.57% |
| YTD return | -0.28% | +53.04% |
| 1-year return | -3.16% | +15.79% |
| 5-year return | -88.27% | -71.43% |
| Forward P/E | 117.33 | — |
| EPS (TTM) | $-0.25 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $2.68 |
| 52-week low | $5.44 | $1.10 |
| Distance from 52-week high | -25.27% | -34.33% |
| Average volume | 105.80K | 2.91M |
| Shares outstanding | 106.03M | 444.96M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed GYRE by 19.0 percentage points over the past year.
GYRE vs LXRX FAQ
Which is bigger, Gyre Therapeutics or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $783.12M compared with $746.48M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, GYRE or LXRX?
LXRX returned +15.79% over the past 12 months, compared with -3.16% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.